Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 5, 2008 - Issue 7
Submit an article Journal homepage
246
Views
54
CrossRef citations to date
0
Altmetric
Review

Drug delivery systems against leishmaniasis? Still an open question

Eder L Romero Universidad Nacional de Quilmes, Programa de Nanomedicinas, Roque Saenz Peña 352, Bernal 1876 BXD, Buenos Aires, Argentina +54 114 365 7100; +54 114 365 7132; [email protected]
&
Maria Jose Morilla Universidad Nacional de Quilmes, Programa de Nanomedicinas, Roque Saenz Peña 352, Bernal 1876 BXD, Buenos Aires, Argentina +54 114 365 7100; +54 114 365 7132; [email protected]
Pages 805-823 | Published online: 01 Jul 2008

Bibliography

  • Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27:305-18
  • Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9
  • Murray HW, Berman JD, Davies RR, et al.Advances in Leishmaniasis. Lancet 2005;366:1561-77
  • Garcia LS, Bruckner DA. Diagnostic medical parasitology. 3rd edition. Washington: ASM Press; 1997
  • Roberts LS Jr, Janovy JJ. Foundations of parasitology. 6th edition. Boston: McGraw Hill; 2000
  • Sundar S, Madhukar R. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 2005;6:2821-9
  • Franke, ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990;113:934-40
  • Uzun S, Durdu M, Culha G, et al. Clinical features, epidemiology and efficacy of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol 2004;90:853-9
  • Davidson RN. Practical guide for treatment of leishmaniasis. Drugs 1998;56:1009-18
  • Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl Med 2002;347:1739-46
  • Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004;38:377-83
  • Thakur CP, Narayan SA. A comparativeevaluation of amphotericin B and sodium antimoy gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004;98:129-38
  • Maurer N, Fenske DB, Cullis PR. Development in liposomal drug delivery systems. Expert Opin Ther 2001;1
  • Lasic DD. Liposomes: from physics to applications. 1st edition. Amsterdam, the Netherlands: Elsevier Sciences; 1995. p.567
  • Black CD, Watson GJ, Ward RJ. The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans R Soc Trop Med Hyg 1977;71:550-2
  • Alving CR, Steck EA, Chapman WL, et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci USA 1978;75:2959-63
  • New RR, Chance ML, Thomas SC, et al. Antileishmanial activity of antimonials entrapped in liposomes. Nature (London) 1978;272:55-6
  • New RR, Chance ML. Treatment of experimental cutaneous leishmaniasis by liposome-entrapped Pentostam. Acta Trop 1980;37:253-6
  • Baillie AJ, Dolan TF, Alexander J, et al. Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection. Int J Pharm 1989;57:23-8
  • Carter KC, Dolan TF, Alexander J, Carter KC. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol 1989;41:87-91
  • New RRC, Chance ML, Heath S. The treatment of experimental cutaneous leishmaniasis with liposome-entrapped Pentostam. Parasitology 1981;83:519-27
  • New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981;8:371-81
  • Lopez-Berestein G, Kasi L, Rosenblum MG, et al. Clinical pharmacology of 99MTC-labeled liposomes in patients with cancer. Cancer Res 1984;44:375-8
  • Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985;151:704-10
  • Berman JD, Hanson WL, Chapman WL, et al. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986;30:847-51
  • Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996;9:512-31
  • Cohen BE. Amphotericin B toxicity and lethality: a tale of two channels. Int J Pharm 1998;162:95-106
  • Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002;49:21-30
  • Davidson RN, Scott A, Maini M, et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. The Lancet 1991;337: 1061-2
  • Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 1991;28:111-8
  • Gradoni L, Davidson RN, Orsini S et al. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target 1993;1:311-6
  • Gangneux JP, Sulahian A, Garin Yjf, et al. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of Ambisome. Antimicrob Agents Chemother 1996;40:1214-8
  • Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994;87:75-81
  • Minodier P, Retornaz K, Horelt A, Garnier JM. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundam Clin Pharmacol 2003;17:183-8
  • Davidson RN, Di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996;22:938-43
  • Russo R, Nigro LC, Minnitis S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose of liposomal amphotericin B (AmBisome). J Infect 1996;32:133-7
  • Laguna F, Torre-Cisneros J, Moreno V, et al. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:711-2
  • Barratt B, Legrand P. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr Opin Infect Dis 2005;18:527-30
  • Bern C, Adler-Moore J, Berenguer J, et al. iposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43:917-24
  • Meyerhoff A. US Food and Drug Administration approval AmBisome (liposomal amphotericin B) for treatment of viseral leishamiasis. Clin Infect Dis 1999;28:42-8
  • Kshirsagar NA, Pandya SK, Kirodian BG, Sanath SS. Liposomal drug delivery systems from laboratory to clinic. J Postgrad Med 2005;51:5-15
  • Sanath SS, Gogtay NJ, Kshirsagar NA. Post-marketing study to assess the safety, tolerability and effectiveness of Fungisome: an Indian liposomal amphotericin B preparation. J Postgrad Med 2005;51:58-63
  • Bodhe PV, Pathare AV, Kshirsagar NA, Pandya SK. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B. J Assoc Physicians India 1996;44:222
  • Gokhale PC, Kshirsagar NA, Khan MU, et al. uccessful treatment of resistant visceral leishmaniasis with liposomal Amphotericin B. Trans R Soc Trop Med Hyg 1994;88:228
  • Karande SC, Boby KF, Lahiri KR, et al. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in a child. Trop Doct 1995;25:80-1
  • Panosian CB, Barza M, Szoka F, Wyler DJ. Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob Agents Chemother 1984;25:655-6
  • Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997;41:752-6
  • Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000;13:243-8
  • Amato VS, Rabello A, Rotondo-Silva A, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop 2004;92:127-32
  • Brown M, NoursadeghI M, Boyle J, Davidson RN. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 2005;153:203-5
  • Rapp C, Imbert P, Darie H, et al. Traitement par amphotéricine B liposomale d´une leishmaniose cutanée contractée à Djibouti et résistante à l´antimoniate de méglumine [Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate]. Bull Soc Pathol Exot 2003;96:209-11
  • Morishige K, Aji T, Ishii A, et al.Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo. Exp Parasitol 1995;80:665-671
  • Cauchetier E, Paul M, Rivollet D, et al. Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int J Parasitol 2000;30:777-83
  • Lala S, Pramanick S, Mukhopadhyay S, et al. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target 2004;2:165-75
  • Papagianaros A, Bories C, Demetzos C, et al. Antileishmanial and trypanocidal activities of new mitelfosine liposomal formulations. Biomed Pharmacother 2005;59:545-50
  • Dey, T, Anam K, Afrin F, Ali N. Antileishmanial Activities of stearylamine-bearing liposomes. Antimicrob Agents Chemother 2000;44:1739-42
  • Pal S, Ravindran R, Ali N. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c mice. Antimicrob Agents Chemother 2004;48:3591-3
  • Allen TM, Mcallister L, Mausolf S, Gyorffy E. Liposome–cell interactions. A study of the interactions of liposomes containing entrapped anti-cancer drugs with the EMT6, S49 and AE1 (transport-deficient) cell lines. Biochem Biophys Acta 1981;643:346-62
  • Olson F, Mayhew E, Maslow D, et al. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982;18:167-76
  • Ghosh P, Bacchawat BK. Grafting of different glycosides on the surface of liposomes and its effect on their tissue distribution of 125I-labelled gamma globulin encapsulated in liposomes. Biochem Biophys Acta 1980;632:562-72
  • Das N, Mahato SB, Naskar K, et al. Targeting of urea stibamine encapsulated in liposomes to reticuloendothelial system for the treatment of experimental leishmaniasis. Biochem Med Metab Biol 1990;43:133-9
  • Medda S, Mukherjee S, Das N, et al. Sugar-coated liposomes: a novel delivery system for increased drug efficacy and reduced drug toxicity. Biotechnol Appl Biochem 1993;17:37-47
  • Banerjee G, Bhaduri AN, Basu MK. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Biochem Med Metab Biol 1994;53:1-7
  • Banerjee G, Nandi G, Mahato SB, et al. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 1996;38:145-50
  • Sinha J, Mukhopadhyay S, Das N, Basu MK. Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Deliv 2000;7:209-13
  • Mitra M, Mandal AK, Chatterjee TK, Das N. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target 2005;13:285-93
  • Gupta CM, Haq W. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections. Meth Enzymol 2005;391:291-304
  • Guru PY, Agrawal AK, Singha UK, et al. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett 1989;245:204-8
  • Agrawal AK, Agrawal A, Pal A, et al. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target 2002;10:41-5
  • Dasgupta D, Chakraborty P, Basu MK. Ligation of Fc receptor of macrophages stimulates protein kinase C and anti-leishmanial activity. Mol Cell Biochem 2000;209:1-8
  • Nakhla T, Marek M, Kovalcik T. Issues associated with large-scale production of liposomal formulations. Drug Delivery Technol 2004;40
  • Wagner A, Vorauer-Uhl K, Katinger H. Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur J Pharm Biopharm 2002;54:213-9
  • Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother 1999;44:791-4
  • Ishida T, Ichihara M, Wang XY, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006;112:15-25
  • Chapman WLJ, Hanson Wl, Alving CR, Hendricks LD. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res 1984;45:1028-30
  • Oliva G, Gradoni L, Ciaramella P, et al.Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995;36:1013-9
  • Alvar J, Molina R, San Andrés MI, et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 1994;88:371-8
  • Baneth G, Shaw SE. Chemotherapy of canine leishmaniasis. Vet Parasitol 2002;106:315-24
  • Uchegbu I, Jeoma F, Florence A. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Coll Int Sci 1995;58:1-55
  • Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm 1999;185:23-5
  • Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol 1988;40:161-5
  • Mullen AB, Baillie AJ, Carter KC. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother 1998;42:2722-5
  • Carter KC, Baillie AJ, Mullen AB. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Clin Diagn Lab Immunol 1999;6:61-5
  • Nieto J, Alvar J, Mullen AB, et al. Pharmacokinetics, toxicities and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother 2003;47:2781-7
  • Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:2089-92
  • Narayanaswami V, Maiorano JN, Dhanasekaran P, et al. Helix orientation of the functional domains in apolipoprotein E in discoidal high density lipoprotein particles. J Biol Chem 2004;279:14273-9
  • Nelson KG, Bishop JV, Ryan RO, Titus R. Nanodisk-associated amphotericin B clears leishmanis major cutaneous infection in susceptible balb/c mice. Antimicrob Agents Chemother 2006;50:1238-44
  • Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Del Rev 2008;60:757-7
  • Veerareddy PR, Vobalaboina V, Nahid A. Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Pharmazie 2004;59:194-7
  • Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 2007;15:437-44
  • Golenser J, Frankenburg S, Ehrenfreund T, Domb AJ. Efficacious treatment of experimental leishmaniasis with amphotericin arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 1999;43:2209-14
  • Ehrenfreund-Kleinman T, Azzam T, Falk R, et al. Synthesis and characterization of novel water-soluble amphotericin B–arabinogalactan conjugates. Biomaterials 2002;23:1327-35
  • Ehrenfreund-Kleinmana T, Golenserb J, Domba AJ. Conjugation of amino-containing drugs to polysaccharides by tosylation: amphotericin B-arabinogalactan conjugates. Biomaterials 2004;25:3049-57
  • Green PJ, Feizi T, Stoll MS, et al. Recognition of the major cell surface glycoconjugates of leishmania parasites by the human serum mannan-binding protein. Mol Biochem Parasitol 1994;66:319-24
  • Nan A, Croft SL, Yardley V, Ghandehari H. Targetable water-soluble polymer–drug conjugates for the treatment of visceral leishmaniasis. J Control Release 2004;94:115-27
  • Gombotz WR, Pettit DK. Biodegradable polymers for protein and peptide drug delivery. Bioconjugate Chem 1995;6:332-51
  • Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release 2003;90:261-80
  • Freitas S, Merkle HP, Gander B. Micorencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release 2005;102:313-32
  • Dea-Ayuela, M.A., Rama-Iñiguez S, Sánchez-Brunete JA, et al. Anti-leishmanial activity of a new formulation of amphotericin B. Trop Med Int Health 2004;9:981-90
  • Sanchez-Brunete A, Dea MA, Rama S, et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004;48:3246-52
  • Ordóñez-Gutiérrez L, Espada-Fernández R, Dea-Ayuela MA, et al. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int J Antimicrob Agents 2007;30:325-9
  • Stjärnkvist P, Artursson P, Brunmark A, et al. Biodegradable microspheres. VIII. Killing of Leishmania donovani in cultured macrophages by microparticle-bound primaquine. Int J Pharm 1987;40:215-22
  • Gaspar R, Oppredoes F, Preat V, Roland M. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann Trop Med Parasitol 1992;86:41-9
  • Gaspar R, Préat V, Roland M. Nanoparticles of polyisohexylcyanoaerylate (PIHCA) as carriers of primaquine: formulation, physico-chemical characterization and acute toxicity. Int J Pharm 1991;68:111-9
  • Gaspar R, Preat V, Oppredoes F, Roland M. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm Res 1992;9:782-7
  • Rodrigues JR Jr, Croft SL, Fessi H, et al. The activity and ultrastructural localization of primaquine-loaded poly(D,L-lactide) nanoparticles in Leishmania donovani infected mice. Trop Med Parasitol 1994;45:223-8
  • Rodrigues JM Jr, Fessi H, Bories C, et al. Primaquine-loaded poly(lactide) nanoparticles: physicochemical study and acute tolerance in mice. Int J Pharm 1995;126:253-60
  • Durand R, Paul M, Rivollet D, et al. Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model. Parasite 1997;4:331-6
  • Durand R, Paul M, Rivollet D, et al. Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. Int J Parasitol 1997;27:1361-7
  • Torres-Santos EC, Rodrigues JMJ, Moreira DL, et al. Improvement of in vitro and in vivo antileishmanial activities of 2′, 6′-dihydroxy-4′-methoxychalcone by entrapmentin poly (D,L-lactide) nanoparticles. Antimicrob Agents Chemother 1999;43:1776-8
  • Espuelas M, Legrand P, Loiseau P, et al. In vitro antileishmanial activity of amphotericin B loaded in poly(e-caprolactone) nanospheres. J Drug Target 2002;10:593-9
  • Medda S, Jaisankar P, Manna RK, et al. Phospholipid microspheres: a novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J Drug Target 2003;11:123-8
  • Lala S, Gupta S, Sahu NP, et al. Critical evaluation of the therapeutic potential of bassic acid incorporated in oil-in-water microemulsions and poly-D,L-lactide nanoparticles against experimental leishmaniasis. J Drug Target 2006;14:171-9
  • Frankenburg S, Glick D, Klaus S, Barenholz Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob Agents Chemother 1998;3092-6
  • Manosroi A, Konkaneramit L, Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int J Pharm 2004;270:279-86
  • Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 2004;30:289-96
  • Muller RH, Jacos C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rational for development and what we can expect for the future. Adv Drug Del Rev 2001;47:3-19
  • Kayser O, Olbrich C, Yardley V, et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003;254:73-5
  • Loftsson T, Brewster ME, Masson M. Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2004;2:261-75
  • Demicheli, C, Ochoa R, Da Silva JBB, et al. Oral delivery of meglumine antimoniate–cyclodextrin complex for treatment of leishmaniasis. Antimicrob Agents Chemother 2004;48:100-3
  • Frézard F, Martins PS, Bahia AP, et al. Enhanced oral delivery of antimony from meglumine antimoniate/beta-cyclodextrin nanoassemblies. Int J Pharm 2008;347:102-8
  • Santiangelo R, Paderu P, Delmas G, et al. Efficacy of oral cochleate–amphotericin B in mouse model of systemic candidiasis. Antimicrob Agents Chemother 2000;44:2356-60
  • Gruda I, Dussault N. Effect of the aggregation state of amphotericin B on its interaction with ergosterol. Biochem Cell Biol 1998;66:177-83
  • Ménez C, Legrand P, Rosilio V, et al. Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B. Mol Pharm 2007;4:218-88
  • Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007;18:26-30
  • Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Del Rev 2007;59:718-28
  • Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006;103:4930-4
  • Goode BL, Drubin DG, Barnes G. Functional cooperation between the microtubule and actin cytoskeleton. Curr Opin Cell Biol 2006;12:63-71
  • Hess H, Tseng Y. Active intracellular transport of nanoparticles: opportunity or threat? ACS Nano 2007;1:390-2
  • Sundar S, Agrawal G, Rai M, et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphoteriricn B: randomized trial. BMJ 2001;323:419-22
  • Murray HW. Progress in treatment of a neglected disease: visceral leishmaniasis. Expert Rev Anti -Infect Ther 2004;2:279-92
  • Vanlerberghe V, Diap G, Guerin J et al. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop Med Int Health 2007;12:274-83
  • Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Del Rev 2001;50:143-56
  • Legrand P, Vertut-Doi D, Bolard J. Comparative internalisation and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 1996;37:519-33
  • van Etten EWM, Otte-Lambillion M, Van Vianen W, et al. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995;35:509-19
  • Gillies ER, Fréchet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;10:35-43
  • Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77
  • Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Del Rev 2004;56:675-711

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.